Mindfulness-Based fMRI Neurofeedback for Depression
Targeting Adolescent Depression Symptoms Using Network-based Real-time fMRI Neurofeedback and Mindfulness Meditation (NIMH); Mindfulness-Based Real-Time fMRI Neurofeedback for Depression (IRB)
Columbia University
90 participants
Apr 10, 2024
INTERVENTIONAL
Conditions
Summary
In the United States, adolescents experience alarmingly high rates of major depression, and gold-standard treatments are only effective for approximately half of patients. Rumination may be a promising treatment target, as it is well-characterized at the neural level and contributes to depression onset, maintenance, and recurrence as well as predicts treatment non-response. Accordingly, the proposed research will investigate whether an innovative mindfulness-based real-time functional magnetic resonance imaging (fMRI) neurofeedback intervention successfully elicits change in the brain circuit underlying rumination to improve clinical outcomes among depressed adolescents.
Eligibility
Inclusion Criteria5
- Ages 13-18 years-old
- Written informed assent/consent and parental/guardian permission for 13-17 year-olds or informed consent for 18 year-olds
- Tanner puberty stage ≥3
- Meets current diagnostic criteria for MDD
- English fluency
Exclusion Criteria8
- Lifetime history of primary psychotic disorders, bipolar disorder, oppositional defiant disorder, conduct disorder, developmental disorder (e.g., autism), post-traumatic stress disorder, or eating disorders
- Substance use disorder, moderate or severe in past 6 months
- Active suicidal ideation with a specific plan
- History of seizure disorder
- Medical or neurological illness (e.g., severe head injury)
- MRI contraindications
- Current psychotropic medication use other than antidepressant medication
- Intelligence quotient (IQ) \<80.
Interventions
Prior to neurofeedback, participants will receive 45 minutes of mindfulness training. Participants will then receive mindfulness-based fMRI neurofeedback targeting the default mode network and frontoparietal control network.
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05617495